The Oncology Institute, Inc.

The Oncology Institute, Inc. (TOI) is a leading provider of highly specialized, value-based cancer care delivered within community settings. Founded in 2007, the company's mission is to heal and empower cancer patients through compassion, innovation, and state-of-the-art medical care. Its corporate headquarters are located in Cerritos, California.

TOI offers a comprehensive suite of medical oncology services, including physician services, in-house infusion and pharmacy, clinical trials, radiation therapy, educational seminars, support groups, counseling, and 24/7 patient assistance. The company also provides palliative care programs and stem cell transplants, traditionally associated with academic and tertiary care settings, bringing these advanced services to the community. TOI primarily serves adult and senior populations, engaging with Medicare (including Medicare Advantage), MediCal, and commercial insurance patients, with a strong focus on value-based care models. The company operates over 100 clinics and affiliate locations across five states—California, Florida, Arizona, Nevada, and Texas—and serves approximately 1.9 million patients through more than 180 employed and affiliate clinicians.

In recent leadership changes, Dr. Daniel Virnich was appointed CEO in June 2023, succeeding Brad Hively, who transitioned to Vice Chairman of the Board. The company further strengthened its executive team with the appointment of Kim Tzoumakas to its Board of Directors in February 2026, Minh Merchant as Chief Legal Officer in April 2026, and the promotions of Rakesh Panda to Chief Information Officer and Nolan Mariano to Chief People Officer in January 2026. TOI has demonstrated strong performance in value-based care, achieving $1.8 million in Medicare savings in the CMS Enhancing Oncology Model Performance Period 3 in April 2026. The company regularly participates in investor conferences and provides financial updates, including its upcoming Q1 2026 earnings release scheduled for May 7, 2026.